ERBB2 and neoplasm: After adjusted for clinicopathologic features including histologic grade, LVI, tumor size, node status, ER, PR, Ki67 level, and sTILs per 10% increment, no RFS difference was found between HER2‐low, HER2‐0, and HER2‐positive patients (p = 0.223; HER2‐low vs. HER2‐0, HR 0.97, 95% CI 0.57–1.64, p = 0.901; HER2‐low vs. HER2‐positive, HR 0.69, 95% CI 0.46–1.05, p = 0.085; HER2‐positive vs. HER2‐0, HR 1.12, 95% CI 0.39–3.25, p = 0.852, Table 3) in multivariate Cox regression model.